Current and Emerging Treatments for Waldenström Macroglobulinemia

Christopher N. Grimont, Natalia E. Castillo Almeida, Morie A. Gertz

Research output: Contribution to journalReview articlepeer-review


Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma. The primary goal of therapy is to reduce symptoms related to direct infiltration of the bone marrow and decrease monoclonal IgM-associated complications. Active agents in the management of WM can be broadly classified as rituximab-alkylator combination therapy, proteasome inhibitor-based therapy, and Bruton's tyrosine kinase inhibitor-based therapy. MYD88L265P and CXCR4 genetic status are pivotal for tailoring treatment options. Ibrutinib is a suitable treatment option for both treatment-naïve and relapsing WM patients. Recent advances in the intracellular B cell and cytokine signaling pathways have contributed to the development of novel therapeutic strategies. Current clinical trials are promising and may further advance WM-directed therapy.

Original languageEnglish (US)
Pages (from-to)146-157
Number of pages12
JournalActa Haematologica
Issue number2
StatePublished - Mar 2021


  • Bendamustine
  • Bruton's tyrosine kinase inhibitors
  • Ibrutinib
  • Proteasome inhibitor
  • Rituximab
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Current and Emerging Treatments for Waldenström Macroglobulinemia'. Together they form a unique fingerprint.

Cite this